|
1
|
World Health Organization, . Non
communicable disease country profiles. 2011, http://www.who.int/nmh/countries/chn_en.pdfAccessed
April 25, 2016.
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN
2012 v1.1, Cancer incidence and mortality worldwide: IARC
CancerBase No. 11 (Internet). International Agency for Research on
Cancer; Lyon, France: 2013 http://globocan.iarc.frAccessed. April
14–2016
|
|
3
|
Sugarbaker PH: Surgery for recurrent colon
cancer. Annintern Med. 130(239): 239–240. 1999.
|
|
4
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Multicenter International Study of
Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of
Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yothers G, O'Connell MJ, Allegra CJ,
Kuebler JP, Colangelo LH, Petrelli NJ and Wolmark N: Oxaliplatin as
adjuvant therapy for colon cancer: Updated results of NSABP C-07
trial, including survival and subset analyses. J Clin Oncol.
29:3768–3774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Steenbergen LN, Elferink MA, Krijnen
P, Lemmens VE, Siesling S, Rutten HJ, Richel DJ, Karim-Kos HE and
Coebergh JW: Working Group Output of The Netherlands Cancer
Registry: Improved survival of colon cancer due to improved
treatment and detection: a nationwide population-based study in The
Netherlands 1989–2006. Ann Oncol. 21:2206–2212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
André T, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F,
et al: Improved overall survival with oxaliplatin, fluorouracil,
and leucovorin as adjuvant treatment in stage II or III colon
cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haller DG, Catalano PJ, Macdonald JS,
O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study
of fluorouracil, leucovorin, and levamisole in high-risk stage II
and III colon cancer: final report of Intergroup 0089. J Clin
Oncol. 23:8671–8678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olontseva OI, Moroz BB, Deshevoĭ Iu B,
Kalistratov GV and Shcherbova EN: Stimulation of the postradiation
recovery of hematopoiesis in irradiated animals using a calf
splenic extract. Radiobiologiia. 29:403–406. 1989.(In Russian).
PubMed/NCBI
|
|
11
|
Guo Y, Hu Q, Sun C, Gu B, Xu K and Xia G:
Postoperative renormalization of C-reactive protein with adjuvant
lienal polypeptide and its association with tumour recurrence in T1
clear cell renal cell carcinoma. J Int Med Res. 44:620–626. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang XE, Wang L, Ji ZQ, Liu MY, Qian T
and Li L: Safety of lienal polypeptide injection combined with
chemotherapy in treating patients with advanced cancer. Asian Pac J
Cancer Prev. 16:7837–7841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry
N and Iacopetta B: Association of tumour site and sex with survival
benefit from adjuvant chemotherapy in colorectal cancer. Lancet.
355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Attard CL, Maroun JA, Alloul K, Grima DT
and Bernard LM: Cost-effectiveness of oxaliplatin in the adjuvant
treatment of colon cancer in Canada. Curr Oncol. 17:17–24.
2010.PubMed/NCBI
|
|
15
|
Twelves C, Boyer M, Findlay M, Cassidy J,
Weitzel C, Barker C, Osterwalder B, Jamieson C and Hieke K: Xeloda
Colorectal Cancer Study Group: Capecitabine (Xeloda) improves
medical resource use compared with 5-fluorouracil plus leucovorin
in a phase III trial conducted in patients with advanced colorectal
carcinoma. Eur J Cancer. 37:597–604. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayvaci MU, Shi J, Alagoz O and Lubner SJ:
Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for
patients with stage II colon cancer. Med Decis Making. 33:521–532.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moertel CG, Fleming TR, Macdonald JS,
Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey
DC, Glick JH, et al: Intergroup study of fluorouracil plus
levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
J Clin Oncol. 13:2936–2943. 1995.PubMed/NCBI
|
|
18
|
Cheng M, Chen Y, Xiao W, Sun R and Tian Z:
NK cell-based immunotherapy for malignant diseases. Cell Mol
Immunol. 10:230–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
